Pictet & Cie Europe Sa Has Decreased Position in Bank Amer (BAC) by $690,350 as Stock Value Declined; As Alexion Pharmaceuticals (ALXN) Market Valuation Declined, Shareholder Opus Point Partners Management Has Lowered Its Holding by $3.30 Million

February 18, 2018 - By Jonathan Benavides

Pictet & Cie Europe Sa decreased its stake in Bank Amer Corp (BAC) by 36.2% based on its latest 2017Q3 regulatory filing with the SEC. Pictet & Cie Europe Sa sold 27,614 shares as the company’s stock declined 6.00% while stock markets rallied. The institutional investor held 48,666 shares of the major banks company at the end of 2017Q3, valued at $1.23 million, down from 76,280 at the end of the previous reported quarter. Pictet & Cie Europe Sa who had been investing in Bank Amer Corp for a number of months, seems to be less bullish one the $328.89 billion market cap company. The stock decreased 0.75% or $0.24 during the last trading session, reaching $31.97. About 62.14 million shares traded. Bank of America Corporation (NYSE:BAC) has risen 58.64% since February 18, 2017 and is uptrending. It has outperformed by 41.94% the S&P500.

Opus Point Partners Management Llc decreased its stake in Alexion Pharmaceuticals Inc (ALXN) by 67.29% based on its latest 2017Q3 regulatory filing with the SEC. Opus Point Partners Management Llc sold 23,553 shares as the company’s stock declined 11.63% while stock markets rallied. The institutional investor held 11,447 shares of the health care company at the end of 2017Q3, valued at $1.61M, down from 35,000 at the end of the previous reported quarter. Opus Point Partners Management Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be less bullish one the $26.71B market cap company. The stock decreased 1.83% or $2.24 during the last trading session, reaching $120.47. About 3.90 million shares traded or 81.87% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since February 18, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.20, from 1.37 in 2017Q2. It is negative, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. 17,211 are owned by Westpac Banking. London Company Of Virginia reported 603,280 shares. Rhumbline Advisers holds 0.12% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 388,315 shares. Andra Ap has 0.03% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 9,000 shares. Fdx Advsrs Inc reported 10,614 shares stake. Retirement Of Alabama has invested 0.12% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Hap Trading Limited Liability Company, New York-based fund reported 13,864 shares. Moreover, Jefferies Group Llc has 0.05% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Bremer Tru National Association, Minnesota-based fund reported 4,099 shares. Serv Automobile Association invested in 118,340 shares or 0.05% of the stock. Victory accumulated 121,142 shares or 0.04% of the stock. Putnam Investments Limited Liability Company holds 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 4,021 shares. Advisor Ltd Llc has invested 0.09% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Chevy Chase Tru invested in 0.12% or 194,893 shares. California State Teachers Retirement invested 0.11% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Opus Point Partners Management Llc, which manages about $111.46 million US Long portfolio, upped its stake in Seattle Genetics Inc (NASDAQ:SGEN) by 6,170 shares to 41,263 shares, valued at $2.25M in 2017Q3, according to the filing.

Since August 28, 2017, it had 0 insider purchases, and 14 sales for $6.68 million activity. Wagner Heidi L sold $16,800 worth of stock. Franchini Indrani Lall sold 1,459 shares worth $169,696. Moriarty John B sold $389,099 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, February 6. The insider HANTSON LUDWIG sold $310,521. Clancy Paul J sold $707,048 worth of stock or 6,079 shares. Shares for $192,028 were sold by Goff Brian.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. As per Friday, July 31, the company rating was maintained by UBS. Leerink Swann maintained the shares of ALXN in report on Wednesday, December 6 with “Buy” rating. The stock has “Buy” rating by Vetr on Wednesday, August 12. On Wednesday, June 7 the stock rating was maintained by Jefferies with “Hold”. On Friday, October 2 the stock rating was upgraded by Morgan Stanley to “Overweight”. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Tuesday, September 12. The company was maintained on Friday, October 20 by BMO Capital Markets. The firm earned “Equal-Weight” rating on Tuesday, December 13 by Morgan Stanley. The rating was maintained by Barclays Capital with “Equal-Weight” on Thursday, February 4. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Nomura on Monday, July 17.

Investors sentiment decreased to 1.04 in Q3 2017. Its down 0.08, from 1.12 in 2017Q2. It dived, as 68 investors sold BAC shares while 569 reduced holdings. 117 funds opened positions while 547 raised stakes. 6.91 billion shares or 9.01% more from 6.34 billion shares in 2017Q2 were reported. Old Mutual (Uk) Limited holds 0.02% or 92,469 shares. Waratah Cap Advsr Limited owns 15,410 shares for 0.05% of their portfolio. Mountain Pacific Invest Advisers Inc Id owns 12,108 shares or 0.03% of their US portfolio. Wright Serv accumulated 96,440 shares. Sfmg Ltd Llc stated it has 8,000 shares or 0.04% of all its holdings. Marco Investment Mngmt Limited Liability Corporation stated it has 0.48% of its portfolio in Bank of America Corporation (NYSE:BAC). Compton Capital Inc Ri invested in 1.13% or 99,644 shares. Van Strum Towne Inc invested in 0.15% or 8,800 shares. Cohen & Steers, a New York-based fund reported 1.24M shares. Hall Laurie J Trustee owns 12,732 shares. Connable Office invested 1.14% in Bank of America Corporation (NYSE:BAC). Ig Management Limited, Manitoba – Canada-based fund reported 6.56M shares. Davidson Garrard owns 349,104 shares for 2.08% of their portfolio. University Of Notre Dame Du Lac holds 1.38% in Bank of America Corporation (NYSE:BAC) or 194,815 shares. Amica Pension Fund Board Of Trustees has 231,736 shares for 0.7% of their portfolio.

Pictet & Cie Europe Sa, which manages about $697.36 million US Long portfolio, upped its stake in Celgene Corp (NASDAQ:CELG) by 6,564 shares to 189,547 shares, valued at $27.64 million in 2017Q3, according to the filing. It also increased its holding in Goldman Sachs Group Inc (NYSE:GS) by 10,764 shares in the quarter, for a total of 11,949 shares, and has risen its stake in Cognizant Technology Solutio (NASDAQ:CTSH).

Among 33 analysts covering Bank of America (NYSE:BAC), 22 have Buy rating, 0 Sell and 11 Hold. Therefore 67% are positive. Bank of America had 106 analyst reports since July 21, 2015 according to SRatingsIntel. Robert W. Baird downgraded Bank of America Corporation (NYSE:BAC) rating on Wednesday, November 16. Robert W. Baird has “Neutral” rating and $18 target. The firm has “Buy” rating by RBC Capital Markets given on Wednesday, June 14. The firm has “Buy” rating by Vetr given on Tuesday, August 11. The firm has “Market Perform” rating given on Monday, May 16 by Keefe Bruyette & Woods. The company was maintained on Thursday, April 7 by JP Morgan. The firm has “Neutral” rating by UBS given on Wednesday, August 26. The firm has “Buy” rating given on Tuesday, September 8 by Nomura. The stock of Bank of America Corporation (NYSE:BAC) earned “Buy” rating by Nomura on Tuesday, July 18. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, April 5. Societe Generale downgraded the shares of BAC in report on Tuesday, January 9 to “Hold” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>